Doravirine/lamivudine/tenofovir
| Combination of | |
|---|---|
| Doravirine | Non-nucleoside reverse transcriptase inhibitor |
| Lamivudine | Nucleoside reverse transcriptase inhibitor |
| Tenofovir disoproxil | Nucleotide reverse transcriptase inhibitor |
| Names | |
| Trade names | Delstrigo |
| Other names | Doravirine/lamivudine/tenofovir disoproxil fumarate, MK-1439A |
| Clinical data | |
| Main uses | HIV/AIDS[1] |
| Side effects | Dizziness, nausea, abnormal dreams[1] |
| WHO AWaRe | UnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽ |
| External links | |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618049 |
| Legal | |
| License data | |
| Legal status | |
Doravirine/lamivudine/tenofovir, sold under the brand name Delstrigo, is a combination medication used to treat HIV/AIDS.[1] It may be used as an initial treatment.[1] It may be the only medication a person requires.[1] It is taken by mouth.[1]
Common side effects include dizziness, nausea, and abnormal dreams.[1] Other side effects may include kidney problems, osteoporosis, and immune reconstitution syndrome.[1] Safety in pregnancy is unclear.[4] It contains doravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), and lamivudine and tenofovir disoproxil, both nucleoside analogue reverse transcriptase inhibitors.[1]
The combination was approved for medical use in the United States and Europe in 2018.[1][3] In the United Kingdom a month of medication costs the NHS about £580 as of 2021.[5] In Canada this amount is about 865 CAD while in the United States it is about 2,260 USD.[6][7]
Medical uses
Dosage
It is taken as a dose of 1 tablet of 100 mg of doravirine, 300 mg of lamivudine, and 300 mg of tenofovir disoproxil fumarate per day.[1][3] In Europe each tablet contains 245 mg of tenofovir disoproxil.[3]
References
- 1 2 3 4 5 6 7 8 9 10 11 12 "Delstrigo- doravirine, lamivudine, and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 10 October 2019. Archived from the original on 1 February 2021. Retrieved 31 July 2020.
- ↑ "Delstrigo 100 mg /300 mg /245 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 8 July 2020. Archived from the original on 28 August 2021. Retrieved 1 October 2020.
- 1 2 3 4 "Delstrigo EPAR". European Medicines Agency (EMA). Archived from the original on 28 October 2020. Retrieved 1 October 2020.
- ↑ "Doravirine / lamivudine / tenofovir (Delstrigo) Use During Pregnancy". Drugs.com. Archived from the original on 22 November 2021. Retrieved 27 December 2021.
- ↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 692. ISBN 978-0857114105.
- ↑ Canadian Agency for Drugs and Technologies in Health (June 2019). "Common Drug Review New Combination Product: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination (Delstrigo)". CADTH Common Drug Reviews. Ottawa (ON). PMID 31393687. Archived from the original on 28 August 2021. Retrieved 3 May 2021.
- ↑ "Delstrigo Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 27 December 2021.
External links
| Identifiers: |
|---|
- "Doravirine". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 27 March 2021. Retrieved 3 May 2021.
- "Lamivudine". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 17 April 2020. Retrieved 3 May 2021.
- "Tenofovir disoproxil". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 25 January 2020. Retrieved 3 May 2021.
- "Tenofovir disoproxil fumarate". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 28 June 2019. Retrieved 3 May 2021.
- "doravirine lamuvidine tenofovir disoproxil fumarate". Canadian Agency for Drugs and Technologies in Health (CADTH). Archived from the original on 20 May 2021. Retrieved 3 May 2021.